Abstract:Background: Drug-induced hyperglycemia and diabetes have negative and potentially serious health consequences but can often be unnoticed. Methods: We reviewed the literature searching Medline database for articles addressing drug-induced hyperglycemia and diabetes up to January 31, 2023. We also selected drugs that could induce hyperglycemia or diabetes according official data from drug information databases Thériaque and Micromedex. For each selected drug or pharmacotherapeutic class, the mechanisms of action potentially involved were investigated. For drugs considered to be at risk of hyperglycemia or diabetes, disproportionality analyses were performed using data from the international pharmacovigilance database VigiBase. In order to detect new pharmacovigilance signals, additional disproportionality analyses were carried out for drug classes with more than 100 cases reported in VigiBase, but not found in the literature or official documents. Results: The main drug classes found to cause hyperglycemia are glucocorticoids, HMG-coA reductase inhibitors, thiazide diuretics, beta-blockers, antipsychotics, fluoroquinolones, antiretrovirals, antineoplastic agents and immunosuppressants. The main mechanisms involved are alterations in insulin secretion and sensitivity, direct cytotoxic effects on pancreatic cells and increases in glucose production. Pharmacovigilance signal were found for a majority of drugs or pharmacological classes identified as being at risk of diabetes or hyperglycemia. We identified new pharmacovigilance signals with drugs not known to be at risk according to the literature or official data: phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, sodium oxybate, biphosphonates including alendronic acid, digoxin, sartans, linosipril, diltiazem, verapamil, and darbepoetin alpha. Further studies will be needed to confirm these signals. Conclusions: The risks of induced hyperglycemia vary from one drug to another, and the underlying mechanisms are multiple and potentially complex. Clinicians need to be vigilant when using at-risk drugs in order to detect and manage these adverse drug reactions. However, it is to emphasize that the benefits of appropriately prescribed treatments most often outweigh their metabolic risks.

Glucose-induced hyperkalaemia: A hazard for diabetics?

Impact of dextrose dose on hypoglycemia development following treatment of hyperkalemia

Pseudohyperglycemia Secondary to High-Dose Intravenous Vitamin C Managed as Diabetic Ketoacidosis: An Endocrinological Catastrophe

The Effect of Glucose and Insulin Infusion on the Fall of Ketone Bodies During Treatment of Diabetic Ketoacidosis

Association of Serum Potassium Homeostasis with Glucose Metabolism in Hospitalized Patients with Type 2 Diabetes

Current hyperkalemia interventions co-administered with a dextrose 10% solution significantly lower hypoglycemic rates (CHICA-D10)

A clinical alert: Oral glucose tolerance test triggering diabetic ketoacidosis in pregnancy

Evaluation of Insulin Dosing Strategies for Hyperkalemia Management at an Academic Medical Center

Hyperglycemia in critical illness: a review

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis

Hyperkalemia Management with Intravenous Insulin in Patients with Reduced Kidney Function

A single oral glucose load decreases arterial plasma [K+ ] during exercise and recovery

Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes

Effect of insulin-induced hypoglycaemia on the central nervous system: evidence from experimental studies

Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression

Drug-induced hyperglycemia and diabetes

Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

Minimizing the risk of brain herniation during treatment of diabetic ketoacidemia: A retrospective and prospective study

Time to Moderate and Severe Hyperglycemia and Ketonemia Following an Insulin Pump Occlusion

Effects of severe hypoglycemia on the human brain. Neuropathological case reports

Euglycemic diabetic ketoacidosis in the setting of acute intracerebral hemorrhage